Melanotan I

Purity: 99.821%
Batch #: MT1-10-601
Verified Potency: 10.50mg
$65.00

Melanotan I is a stabilized peptide analog of α-MSH investigated for its interaction with melanocortin receptors, natural pigmentation processes, and protective skin response pathways.

Ships by Calculating...
Disclaimer
For Research Use Only. Not for human consumption or therapeutic treatment.

About Melanotan I

Melanotan I (also known as Afamelanotide) is an enhanced analog of alpha-melanocyte-stimulating hormone (α-MSH), engineered for superior stability and sustained activity in research settings. Scientists explore its precise interaction with melanocortin receptors—particularly MC1R—to better understand natural tanning mechanisms, melanin production, and the skin's inherent defense systems against environmental stressors. Research also investigates Melanotan I's potential influence on inflammatory signaling through melanocortin pathways. Its robust stability profile and well-characterized receptor interactions have made it an essential tool in dermatological research and melanocortin biology studies.

Product Specifications
Melanotan I Lyophilized Powder in 3ml vial
Application
Melanocortin receptor and pigmentation pathway research
Appearance
Solid, white powder in 3mL glass ampule
Chemical Formula
C78H111N21O19
CAS number
75921-69-6
Molecular Weight
~1646.9 g/mol

FAQs

What is Melanotan I?
Melanotan I, also known as afamelanotide, is a synthetic analog of alpha-melanocyte-stimulating hormone consisting of 13 amino acids. It is a linear peptide that activates the melanocortin-1 receptor, which regulates melanin production in melanocytes. Melanotan I was developed at the University of Arizona by Victor Hruby and Mac Hadley. Afamelanotide has received regulatory approval in the European Union under the brand name Scenesse for the treatment of erythropoietic protoporphyria, a rare photosensitivity disorder.
Melanotan I binds to the melanocortin-1 receptor on melanocytes and activates adenylyl cyclase, increasing intracellular cyclic AMP levels. This activates protein kinase A, which phosphorylates the transcription factor CREB, leading to increased expression of microphthalmia-associated transcription factor. MITF then upregulates the expression of tyrosinase, tyrosinase-related protein-1, and dopachrome tautomerase, which are the enzymes in the melanin biosynthesis pathway.
Melanotan I is a 13-amino acid linear peptide with high selectivity for the melanocortin-1 receptor, which mediates pigmentation. Melanotan II is a shorter, cyclic 7-amino acid peptide that activates multiple melanocortin receptor subtypes, including MC1R, MC3R, MC4R, and MC5R. This broader receptor activity gives Melanotan II additional effects on sexual function and appetite that Melanotan I does not produce. The two peptides differ in both structure and pharmacological profile.
Afamelanotide (Melanotan I) received approval from the European Medicines Agency in 2014 under the brand name Scenesse as an implant for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria. The FDA approved it in the United States in 2019 for the same indication. Erythropoietic protoporphyria is a genetic condition where accumulation of protoporphyrin IX in the skin causes severe pain upon light exposure, and afamelanotide increases eumelanin production to provide photoprotection.
Limitless Peptides sells Melanotan I as a lyophilized powder in a sealed 3mL glass ampule. The product is Janoshik verified for identity, potency, and purity. Melanotan I is sold for research use only and is separate from the pharmaceutical formulation approved for erythropoietic protoporphyria. The product page includes the manufacturer's certificate of analysis and a link to the independent Janoshik verification report.